anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Edaravone
Trial phase: Phase 4
ATC code: N07XX14
SMILES: CC1=NN(c2ccccc2)C(=O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 194
Group description: Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
Eligibility criteria:
Inclusion Criteria:

Patients can be receive drug treatment within 24 hours after stroke onset
Patients with a level of consciousness between 0 (alert) and 3 (unable to recall name and date of birth) according to the Japan Coma Scale
Patients with motor dysfunction of upper and/or lower extremities
Patients aged 20 years or older when giving informed consent

Exclusion Criteria:

Serum creatinine of >1.5 mg/dL
Embolic infarction
Intracranial haemorrhage
Large infarction with severe consciousness
Transient ischemic attack (TIA)
A modified Rankin Scale score of ≥2 before stroke onset
Patients were receive drug treatment (argatroban, urokinase, tissue plasminogen activator, heparin, warfarin sodium, aspirin, ticlopidine hydrochloride, cilostazol, edaravone and sodium ozagrel) after stroke onset
Patients were receive surgical treatment or intravascular treatment
With severe complications (cirrhosis, heart failure, etc.)
Treating malignant tumor
Pregnant or possibly pregnant women, nursing mothers
History of edaravone, sodium ozagrel and ozagrel hydrochloride sensitivity
Less than 3 months since any other clinical trial or postmarketing study
Intervention: Ozagrel sodium
Trial phase: Phase 4
SMILES: O=C([O-])C=Cc1ccc(Cn2ccnc2)cc1.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 198
Group description: Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
Eligibility criteria:
Inclusion Criteria:

Patients can be receive drug treatment within 24 hours after stroke onset
Patients with a level of consciousness between 0 (alert) and 3 (unable to recall name and date of birth) according to the Japan Coma Scale
Patients with motor dysfunction of upper and/or lower extremities
Patients aged 20 years or older when giving informed consent

Exclusion Criteria:

Serum creatinine of >1.5 mg/dL
Embolic infarction
Intracranial haemorrhage
Large infarction with severe consciousness
Transient ischemic attack (TIA)
A modified Rankin Scale score of ≥2 before stroke onset
Patients were receive drug treatment (argatroban, urokinase, tissue plasminogen activator, heparin, warfarin sodium, aspirin, ticlopidine hydrochloride, cilostazol, edaravone and sodium ozagrel) after stroke onset
Patients were receive surgical treatment or intravascular treatment
With severe complications (cirrhosis, heart failure, etc.)
Treating malignant tumor
Pregnant or possibly pregnant women, nursing mothers
History of edaravone, sodium ozagrel and ozagrel hydrochloride sensitivity
Less than 3 months since any other clinical trial or postmarketing study
Intervention: Paroxetine
Trial phase: Not Applicable
ATC code: N06AB05
SMILES: Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Paroxetine is a Selective Serotonin Reuptake Inhibitor. Dose started and maintained at 20 mg q10A.
Eligibility criteria:
Inclusion Criteria:

Hazardous duty in Iraq or Afghanistan with the US Armed Forces during Operations Iraqi Freedom and Operation Enduring Freedom
Exposure to at least a moderate level of combat (>5 on Revised Combat Exposure Scale)
Good general medical health
Stable dose of non-excluded medications for at least 4 weeks prior to randomization
>5 on CAPS recurrent distressing dreams item
>5 on CAPS difficulty falling or staying asleep item

Exclusion Criteria:

Acute or significant chronic medical illness, preexisting hypotension or orthostatic hypotension, pancreatitis, gout, Ménière's disease, benign positional vertigo, narcolepsy, or any other unstable medical condition.
Women of childbearing potential with either positive pregnancy test or refusal to use effective birth control method will be excluded.
Lifetime schizophrenia, schizoaffective disorder, bipolar disorder, psychotic disorder or any Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) cognitive disorder, current delirium, substance dependence disorder within 3 months of the study, severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others.
Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist or paroxetine or any other SSRI, no concurrent use of another alpha-1 antagonist agent, no concurrent use of an antidepressant (other than trazodone prescribed for sleep).
Intervention: Erbitux
Trial phase: Phase 2
SMILES: C=C1N(CCCCCC(=O)O)c2ccccc2C1(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.
ECOG performance status 0-2
Patients must have been previously treated with one platinum-containing or taxane-containing chemotherapy regimen for locally advanced or metastatic disease. Patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.
No more than two prior systemic anti-cancer therapies will be allowed.
Prior radiation therapy is allowed to <25% of the bone marrow. Prior radiation to the whole pelvis is not allowed, Prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.
Patients must have signed an approved informed consent.
Male and female patients with reproductive potential must use an approved contraceptive method if appropriate (eg, intrauterine device, birth control pills, or barrier device) during and for 3 months after the study. Female patients must either not be of child bearing potential or have a negative pregnancy test within 7 days of treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
Age>18
Measurable disease in accord with RECIST criteria
Bone marrow Function: absolute neutrophil count (ANC)>/=1,500/ul, platelets >/=l00,000, hemoglobin> 9g/dL
Renal function: creatinine clearance (calculated by Cockcroft and Gault method) >/= 45mL/min
Hepatic function: bilirubin </=1.5 x ULN; ALT/AST ,/= 2.5 x ULN; Albumin >/=2.5 g/dL

Exclusion Criteria:

Prior treatment with pemetrexed
Prior therapy that targets the EGF pathway.
Active or uncontrolled infection.
Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, and congestive heart failure.
Pleural or pericardial effusions that cannot be completely evacuated prior to pemetrexed therapy.
Acute hepatitis or known HIV.
Prior severe infusion reaction to a monoclonal antibody.
Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).
Pregnancy or Breast-feeding.
Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
Inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.
Inability or unwillingness to take folic acid or vitamin B12 supplementation.
Intervention: Lansoprazole
Trial phase: Phase 4
ATC code: A02BC03 | A02BC06 | A02BC53 | A02BD02 | A02BD03 | A02BD07 | A02BD09 | A02BD10
SMILES: Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 72
Group description: This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
Eligibility criteria:
Inclusion Criteria:

Diagnosed with Zollinger-Ellison syndrome

Exclusion Criteria:

Pregnant or lactating females
Intervention: Prednisone
Trial phase: Phase 4
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Prednisone 20mg daily x 2 weeks

prednisone: 20mg x 2 weeks
Eligibility criteria:
Inclusion Criteria:

Must meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for PTSD w/ symptom exacerbation (CAPS score ≥ 50)
Stable on other psychotropic meds x1 month

Exclusion Criteria:

Current or past history of bipolar, schizophrenic, or other psychotic disorder
Organic mental disorder
Alcohol or substance abuse in last 3 months
Clinically significant hepatic or renal disease or other acute or unstable medical condition
Chronic obstructive pulmonary disease (COPD), asthma, uncontrolled diabetes, rheumatologic diseases
Intervention: (10E,12Z)-octadecadienoic acid
Trial phase: Phase 2
SMILES: CCCCC/C=C\C=C\CCCCCCCCC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 24
Group description: 4 grams per day of sunflower oil for 6 months
Eligibility criteria:
Inclusion Criteria:

BMI 25-29.9 kg/m2
Absence of a weight change of greater than 3 kg in the previous 6 months

Exclusion Criteria:

Presence of a physical limitation to walking exercise
Current or recent (6 months) enrollment in a commercial or self-prescribed weight loss program
A history of metabolic disease-ie. renal, endocrine, hepatic or gastrointestinal disease that would impact the outcome of the study
A history of a psychiatric or eating disorders Ÿ Presence of metal implants that would interfere with body composition analysis
Fasting plasma cholesterol >300mg/dl or triglycerides above 500 mg/dl.
Abnormal EKG
Intervention: Cidofovir
Trial phase: Phase 4
ATC code: J05AB12
SMILES: Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
Eligibility criteria:
Inclusion Criteria:

4 surgeries for RRP in last 12 months

Exclusion Criteria:

Renal insufficiency
Nephrotoxic drugs in the last 7 days
Sulfa allergies
Currently treated with systemic or topical HPV chemotherapeutic agents
Females of childbearing potential with a positive pregnancy test
Women who are breast feeding
Intervention: Aripiprazole
Trial phase: Phase 4
ATC code: N05AX12
SMILES: O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 49
Group description: Participants in this group were randomized to treatment with aripiprazole.
Eligibility criteria:
Inclusion Criteria:

Aged 6-18 years
Generally healthy and a score of ≥ 18 on the Aberrant Behavior Checklist in the context of one or more Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) childhood psychiatric disorders, including conduct disorder, oppositional defiant disorder, disruptive behavior disorder, autism, pervasive developmental disorder, attention deficit disorder, schizophrenia and bipolar affective disorders
Children's Global Assessment Scale (CGAS) score ≤ 60
Not previously treated with an antipsychotic; individual subjects with remote, brief prior antipsychotic exposure may be considered for enrollment by the PI on a case by case basis
Patient assent and informed consent obtained from the parent or guardian
No clinically significant (based on PI determination) changes in permitted medications (e.g., stimulants and selective serotonin reuptake inhibitors [SSRIs]) for approximately 1 month prior to Baseline evaluations

Exclusion Criteria:

Active suicidality or primary dx of major depressive disorder
Any lifetime use of antipsychotics or non-serotonin selective reuptake inhibitor (non-SSRI) anti-depressants

The presence of any serious medical disorder, based on PI determination, that may confound the assessment of relevant biologic measures or diagnoses, including:

significant organ system dysfunction;
endocrine disease, including type 1 or type 2 diabetes mellitus;
coagulopathy;
anemia;
or acute infection.
Subjects regularly taking any glucose lowering agent, lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or any other endocrine agent that might confound substrate metabolism, oral glucocorticoids (glucocorticoid inhalants and nasal sprays are permitted), antihistamines, sedating antihistamines (non-sedating antihistamines such as but not limited to Claritin (loratadine) and Zyrtec (cetirizine) are permitted), and certain mood stabilizing agents, as some medications may themselves worsen or otherwise alter weight gain, glucose and lipid regulation or otherwise make it difficult to assess the effects of the antipsychotic alone; (note that exposure to many psychotropic agents including stimulants and SSRI's is permitted in order to maintain the generalizability of the sample);
Intelligence quotient (IQ) < 70 (based on school records and/or evaluation by clinician)
current substance abuse
Past history or currently has dyskinesia
Stimulant dosage significantly higher (per PI judgment)than the equivalent of approximately 2mg/kg/day methylphenidate equivalent dose.
Intervention: Olanzapine
Trial phase: Phase 4
ATC code: N05AH03 | N05AH53
SMILES: Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Participants in this group were randomized to treatment with olanzapine.
Eligibility criteria:
Inclusion Criteria:

Aged 6-18 years
Generally healthy and a score of ≥ 18 on the Aberrant Behavior Checklist in the context of one or more Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) childhood psychiatric disorders, including conduct disorder, oppositional defiant disorder, disruptive behavior disorder, autism, pervasive developmental disorder, attention deficit disorder, schizophrenia and bipolar affective disorders
Children's Global Assessment Scale (CGAS) score ≤ 60
Not previously treated with an antipsychotic; individual subjects with remote, brief prior antipsychotic exposure may be considered for enrollment by the PI on a case by case basis
Patient assent and informed consent obtained from the parent or guardian
No clinically significant (based on PI determination) changes in permitted medications (e.g., stimulants and selective serotonin reuptake inhibitors [SSRIs]) for approximately 1 month prior to Baseline evaluations

Exclusion Criteria:

Active suicidality or primary dx of major depressive disorder
Any lifetime use of antipsychotics or non-serotonin selective reuptake inhibitor (non-SSRI) anti-depressants

The presence of any serious medical disorder, based on PI determination, that may confound the assessment of relevant biologic measures or diagnoses, including:

significant organ system dysfunction;
endocrine disease, including type 1 or type 2 diabetes mellitus;
coagulopathy;
anemia;
or acute infection.
Subjects regularly taking any glucose lowering agent, lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or any other endocrine agent that might confound substrate metabolism, oral glucocorticoids (glucocorticoid inhalants and nasal sprays are permitted), antihistamines, sedating antihistamines (non-sedating antihistamines such as but not limited to Claritin (loratadine) and Zyrtec (cetirizine) are permitted), and certain mood stabilizing agents, as some medications may themselves worsen or otherwise alter weight gain, glucose and lipid regulation or otherwise make it difficult to assess the effects of the antipsychotic alone; (note that exposure to many psychotropic agents including stimulants and SSRI's is permitted in order to maintain the generalizability of the sample);
Intelligence quotient (IQ) < 70 (based on school records and/or evaluation by clinician)
current substance abuse
Past history or currently has dyskinesia
Stimulant dosage significantly higher (per PI judgment)than the equivalent of approximately 2mg/kg/day methylphenidate equivalent dose.
Intervention: Risperidone
Trial phase: Phase 4
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 49
Group description: Participants in this group were randomized to treatment with risperidone.
Eligibility criteria:
Inclusion Criteria:

Aged 6-18 years
Generally healthy and a score of ≥ 18 on the Aberrant Behavior Checklist in the context of one or more Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) childhood psychiatric disorders, including conduct disorder, oppositional defiant disorder, disruptive behavior disorder, autism, pervasive developmental disorder, attention deficit disorder, schizophrenia and bipolar affective disorders
Children's Global Assessment Scale (CGAS) score ≤ 60
Not previously treated with an antipsychotic; individual subjects with remote, brief prior antipsychotic exposure may be considered for enrollment by the PI on a case by case basis
Patient assent and informed consent obtained from the parent or guardian
No clinically significant (based on PI determination) changes in permitted medications (e.g., stimulants and selective serotonin reuptake inhibitors [SSRIs]) for approximately 1 month prior to Baseline evaluations

Exclusion Criteria:

Active suicidality or primary dx of major depressive disorder
Any lifetime use of antipsychotics or non-serotonin selective reuptake inhibitor (non-SSRI) anti-depressants

The presence of any serious medical disorder, based on PI determination, that may confound the assessment of relevant biologic measures or diagnoses, including:

significant organ system dysfunction;
endocrine disease, including type 1 or type 2 diabetes mellitus;
coagulopathy;
anemia;
or acute infection.
Subjects regularly taking any glucose lowering agent, lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or any other endocrine agent that might confound substrate metabolism, oral glucocorticoids (glucocorticoid inhalants and nasal sprays are permitted), antihistamines, sedating antihistamines (non-sedating antihistamines such as but not limited to Claritin (loratadine) and Zyrtec (cetirizine) are permitted), and certain mood stabilizing agents, as some medications may themselves worsen or otherwise alter weight gain, glucose and lipid regulation or otherwise make it difficult to assess the effects of the antipsychotic alone; (note that exposure to many psychotropic agents including stimulants and SSRI's is permitted in order to maintain the generalizability of the sample);
Intelligence quotient (IQ) < 70 (based on school records and/or evaluation by clinician)
current substance abuse
Past history or currently has dyskinesia
Stimulant dosage significantly higher (per PI judgment)than the equivalent of approximately 2mg/kg/day methylphenidate equivalent dose.
Intervention: Quetiapine
Trial phase: Phase 4
ATC code: N05AH04
SMILES: OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 586
Group description: Quetiapine fumarate - flexibly dosed (200 - 800 mg/day)
Eligibility criteria:
Inclusion Criteria:

Men and women age 18 to 65
Both Eyes present with lenses intact (no previous cataract extractions)
Stable place of residency

Exclusion Criteria:

History of corneal surgery
Legal blindness (defined as best corrected visual acuity of 20/200 or worse in one or both eyes
Previous participation in this study
Intervention: Risperidone
Trial phase: Phase 4
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 496
Group description: Risperidone - flexibly dosed (2 - 8 mg/day)
Eligibility criteria:
Inclusion Criteria:

Men and women age 18 to 65
Both Eyes present with lenses intact (no previous cataract extractions)
Stable place of residency

Exclusion Criteria:

History of corneal surgery
Legal blindness (defined as best corrected visual acuity of 20/200 or worse in one or both eyes
Previous participation in this study
Intervention: Valsartan
Trial phase: Phase 2
ATC code: C09CA03 | C09DA03 | C09DB01 | C09DB08 | C09DX01 | C09DX02 | C09DX04 | C09DX05 | C10BX10
SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Valsartan titrated up to 320 mg orally daily

Valsartan: Valsartan was titrated to a target dose of 320 mg orally daily
Eligibility criteria:
Inclusion Criteria:

> 0.65 mm intima-media thickness of the carotid artery measured by ultrasound
Males aged 21-80 years or women without child bearing potential up to age 80
Can be on concomitant therapy with aspirin, thiazide diuretics, calcium antagonists (for treatment of hypertension), or beta-receptor antagonists.
May be on statin if on stable dose for at least 2 months before recruitment

Exclusion Criteria:

Angiotensin-converting enzyme (ACE) inhibitor or ARB therapy in the previous 3 months.
Initiation or change in dose of statin therapy within 2 months before the study
Inability to return to Emory for follow-up blood drawing and MR imaging
Age < 21 or > 80 years
Premenopausal females with potential for pregnancy
Current neoplasm
Chronic renal failure [creatinine > 2.5 mg/dL]
Diabetes with hemoglobin (Hb) A1c > 8.5
Anticipated change in lipid lowering therapy
Inability to give informed consent
MR exclusion criteria
Blood pressure > 140 mmHg systolic and > 90 mmHg diastolic
Low-density lipoprotein (LDL) cholesterol level >130 mg/dl
Acute coronary syndrome within 2 months
Acute cerebrovascular accident within 2 months
Intervention: Tamsulosin
Trial phase: Not Applicable
ATC code: G01AE10 | G04CA02 | G04CA52 | G04CA53 | G04CA54
SMILES: CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
Eligibility criteria:
Inclusion Criteria:

Patients 18 years old and above with urolithiasis scheduled for shock wave lithotripsy.

Exclusion Criteria:

Contraindications to Flomax
Patients with renal impairment (serum creatinine above 2.0)
Patients with hepatic impairment (liver enzymes 2.5 times the upper limit of normal)
Use of other oral alpha blockers
Intervention: Iodixanol
Trial phase: Phase 4
ATC code: V08AB09
SMILES: CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 321
Group description: Iodixanol 320 mg I/mL

Iodixanol 320-Arm 1
Eligibility criteria:
Inclusion Criteria:

Patients with a combination of diabetes mellitus (type I or II) and renal impairment who are referred for a contrast-enhanced CT examination.

Exclusion Criteria:

Concurrent administration of potentially nephroprotective or nephrotoxic drugs is not permitted.
Patients undergoing dialysis or kidney transplantation will not be included.